View in EDS HTML Full Text PDF Full Text

Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Saved in:
Bibliographic Details
Title: Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Authors: Palomo L; Josep Carreras Leukaemia Research Institute, ICO Badalona-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Sadalona, Spain., Ibáñez M; Department of Haematology, Hospital Universitari i Politècnic La Fe, València, Spain.; Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain.; Departamento de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, València, Spain., Abáigar M; Institute of Biomedical Research of Salamanca (IBSAL), Cancer Research Centre (IBMCC-CIC; Univ. of Salamanca-CSIC), Salamanca, Spain., Vázquez I; Haematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Álvarez S; NIMGenetics, Genómica y Medicina, S.L., Madrid, Spain., Cabezón M; Haematology Service, ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Badalona, Spain., Tazón-Vega B; Department of Haematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain., Rapado I; Haematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.; Haematological Malignancies Clinical Research Unit, CNIO, Madrid, Spain.; Centro de investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain., Fuster-Tormo F; Josep Carreras Leukaemia Research Institute, ICO Badalona-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Sadalona, Spain., Cervera J; Department of Haematology, Hospital Universitari i Politècnic La Fe, València, Spain.; Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain.; Genetics Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Benito R; Institute of Biomedical Research of Salamanca (IBSAL), Cancer Research Centre (IBMCC-CIC; Univ. of Salamanca-CSIC), Salamanca, Spain., Larrayoz MJ; Haematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Cigudosa JC; NIMGenetics, Genómica y Medicina, S.L., Madrid, Spain., Zamora L; Haematology Service, ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Badalona, Spain., Valcárcel D; Department of Haematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain., Cedena MT; Haematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.; Haematological Malignancies Clinical Research Unit, CNIO, Madrid, Spain.; Centro de investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain., Acha P; Josep Carreras Leukaemia Research Institute, ICO Badalona-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Sadalona, Spain., Hernández-Sánchez JM; Institute of Biomedical Research of Salamanca (IBSAL), Cancer Research Centre (IBMCC-CIC; Univ. of Salamanca-CSIC), Salamanca, Spain.; University of Salamanca (USAL), Salamanca, Spain., Fernández-Mercado M; Haematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.; Advanced Genomics Laboratory, Centre for Applied Medical Research (CIMA), University of Navarra, Haemato-Oncology, Pamplona, Spain.; Biomedical Engineering Department, School of Engineering, University of Navarra, San Sebastian, Spain., Sanz G; Department of Haematology, Hospital Universitari i Politècnic La Fe, València, Spain.; Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain., Hernández-Rivas JM; Institute of Biomedical Research of Salamanca (IBSAL), Cancer Research Centre (IBMCC-CIC; Univ. of Salamanca-CSIC), Salamanca, Spain.; University of Salamanca (USAL), Salamanca, Spain.; Hospital Universitario de Salamanca, Salamanca, Spain., Calasanz MJ; Haematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Solé F; Josep Carreras Leukaemia Research Institute, ICO Badalona-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Sadalona, Spain., Such E; Department of Haematology, Hospital Universitari i Politècnic La Fe, València, Spain.; Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain.; Departamento de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, València, Spain.
Corporate Authors: Spanish Group of MDS (GESMD)
Source: British journal of haematology [Br J Haematol] 2020 Mar; Vol. 188 (5), pp. 605-622. Date of Electronic Publication: 2019 Oct 16.
Publication Type: Letter; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1365-2141
DOI:10.1111/bjh.16175